EVX-02
- Generic Name
- EVX-02
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
Phase 1
Terminated
- Conditions
- Melanoma Stage IVMelanoma Stage III
- Interventions
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Evaxion Biotech A/S
- Target Recruit Count
- 15
- Registration Number
- NCT04455503
- Locations
- 🇦🇺
Ballarat Health Services, Drummond, Victoria, Australia
🇦🇺Liverpool Hospital, Goulburn, New South Wales, Australia
🇦🇺Linear Cancer Trials, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath